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Abstract
Background:  Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa)
suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage
(ICH) is safe, limits ICH growth, and improves outcomes. We sought to determine the cost-
effectiveness of rFVIIa for acute ICH treatment, using published Phase II data. We hypothesized that
rFVIIa would have a low marginal cost-effectiveness ratio (mCER) given the poor neurologic
outcomes after ICH with conventional management.
Methods: We performed an incremental cost-effectiveness analysis from the societal perspective,
considering conventional management vs. 80 ug/kg rFVIIa treatment for acute ICH cases meeting
Phase II inclusion criteria. The time frame for the analysis was 1. 25 years: data from the Phase II
trial was used for 90 day outcomes and rFVIIa complications – arterial thromboembolic events
(ATE). We assumed no substantial cost differences in care between the two strategies except: 1)
cost of rFVIIa (for an 80 mcg/kg dose in an 80 kg patient, assumed cost of $6,408); 2) cost of ATE
side effects from rFVIIa (which also decrease quality of life and increase the chance of death); and
3) differential monetary costs of outcomes and their impact on quality of life, including disposition
(home vs. nursing home), and outpatient vs. inpatient rehabilitation. Sensitivity analyses were
performed to explore uncertainty in parameter estimates, impact of rFVIIa cost, direct cost of
neurologic outcomes, probability of ATE, and outcomes after ATE.
Results: In the "base case", treating ICH with rFVIIa dominates the usual care strategy by being
more effective and less costly. rFVIIa maintained a mCER < $50,000/QALY over a wide range of
sensitivity analyses. Sensitivity analyses showed that the cost of rFVIIa must exceed $14,500, or the
frequency of ATE exceed 29%, for the mCER to exceed $50,000/QALY. Varying the cost and/or
reducing the utility of health states following ATE did not impact results.
Conclusion: Based on data from preliminary trials, treating selected ICH patients with rFVIIa
results in lower cost and improved clinical outcomes. This potential cost-effectiveness must be
considered in light of the Phase III trial results.
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Background
The majority of strokes worldwide are ischemic. Ischemic
stroke victims that present within three hours are eligible
for thrombolytic treatment with intravenous recombinant
tissue plasminogen activator (r-tPA). This is a costly med-
ication (retail price is approximately $2000) that is cur-
rently only given to a minority of patients [1,2]. Despite
high costs and low utilization, the use of r-tPA is "cost-
effective" at the population level over a 30 year time hori-
zon [3].
While intracerebral hemorrhage (ICH) is much less com-
mon (approximately 10% of all strokes in the US),[4] it is
a disease with high mortality and cost to society. Mortality
at 30 days is 40–60% [4-6]A previous study in Cincinnati
showed that many intracerebral clots expand in the short
term; 38% of ICH's had > 33% expansion in first three
hours and clot expansion was significantly associated with
increased mortality and morbidity [7]. There are currently
no medical therapies for ICH, and surgery to remove the
blood clot is usually reserved only for severe, life-threaten-
ing ICH.
Recombinant factor VIIa (rFVIIa) is currently FDA-
approved for the treatment of patients with hemophilia.
Given its thrombogenic effects, it was hypothesized that it
might be useful for limiting clot expansion in patients
with acute ICH. Phase I and II placebo-controlled trials of
rFVIIa have been completed in acute ICH patients [8,9].
These studies have demonstrated that administration of
rFVIIa within the first 4 hours after onset of ICH symp-
toms is safe, limits ICH growth, and improves outcomes.
Data from the Phase II trial (testing 3 doses) showed a
dose effect, in that the 80 ug/kg dose was more effective
than the 40 ug/kg dose. The 160 ug/kg dose results were
not substantially better than for the 80 ug/kg dose, and
the higher dose was associated with a slight increase in
adverse events (serious thromboembolic events) [9]. ICH
growth was 29% in the placebo arm as compared to 14%
in the 80 mcg/kg group; mortality at 90 days was reduced
from 29% in the placebo arm to 18% in the 80 mcg/kg
rFVIIa arm. Safety was acceptable, but treatment was asso-
ciated with a 2% risk of thromboembolic events.
Results from a phase III trial comparing the efficacy of 80
ug/kg rFVIIa vs. 20 ug/kg rFVIIa vs. placebo have been pre-
sented (by Stephan Mayer et al, at the 59th Annual Meeting
of the American Academy of Neurology, April 2007) but
not yet published at the time of this writing. This trial did
not demonstrate a clinical benefit for rFVIIa over placebo.
However, a similar biologic effect was seen with regard to
prevention of clot expansion.
Given the contradictory findings of the phase II and phase
III trials, and the many issues raised about the phase III
study, including questions regarding inclusion criteria
and the surprisingly good outcomes in the placebo arm,
there undoubtedly will be further discussion about the
possibility of future trials.
In light of these issues, we wished to explore the cost-effec-
tiveness of rFVIIa across a spectrum of neurological out-
comes and efficacy of treatment, in order to better
understand just how effective rFVIIa would have to be in
order to be "cost-effective" for the acute treatment of ICH
given the high cost and poor neurological outcomes in
patients with acute ICH receiving conventional care. We
studied this question by constructing a decision analytic
model using published Phase II data for our base case
analysis. Thus, we compared the neurological outcomes
from the placebo arm (usual care; no treatment) of the
Phase II trial to the results of treatment with rFVIIa at 80
ug/kg. We examined the impact of decreasing the efficacy
of rFVIIa in preventing major neurological sequelae and
death on the resultant cost-effectiveness of treatment.
Methods
We used a standard computer program (Decision
Maker)[10] to construct and analyze decision trees and to
perform sensitivity analyses. Our analysis compares con-
ventional supportive management (the current standard
of care, as there are no other medical treatments for ICH)
to treatment with rFVIIa (see Figure 1). We performed our
cost-effectiveness analysis from a societal perspective,
considering the decision only for those cases of ICH that
would have met inclusion criteria in the Phase II trial. Pre-
vious estimates from a population- based study of ICH
suggest that 13–17% of all ICH's would present within the
4 hour time window and be eligible; the most common
exclusions from the Phase II trial were time to presenta-
tion and symptomatic thrombotic or vaso-occlusive dis-
ease within 30 days prior to ICH onset [11]. Sensitivity
analyses were performed to explore uncertainty in param-
eter estimates, including the efficacy of rFVIIa in prevent-
ing major neurological sequelae and death. Further
sensitivity analyses were performed to explore the impact
of changes in the cost of rFVIIa, the direct costs of neuro-
logical outcomes, the probability of ATE, and outcomes
after ATE. A marginal cost-effectiveness ratio (mCER) less
than or equal to $50,000/QALY was considered to be
below the threshold for societal 'willingness to pay', thus
representing a reasonable expenditure of societal
resources for the benefit gained.
Decision Model Structure and Assumptions
Model Structure and Parameters
We used the modified Rankin Scale (mRS) to describe
neurological outcomes as in the Phase II trial. 9 Thus,
patients receiving conventional management (lower
branch of the decision node in Figure 1), may experienceBMC Neurology 2008, 8:17 http://www.biomedcentral.com/1471-2377/8/17
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a range of neurological outcomes based on the distribu-
tion of 90 day mRS outcomes in the placebo arm in the
Phase II trial.
Patients receiving treatment with rFVIIa (upper branch of
the decision node) accrue the incremental cost of the
drug. They next face the risk of arterial thromboembolism
(ATE), the major adverse event associated with the use of
rFVIIa. Patients who experience an ATE (either an
ischemic stroke or myocardial infarction) may either die
or survive. If they survive, they accrue additional costs for
the care provided due to the ATE and also have a reduced
quality of life due primarily to long-term neurological
morbidity from ischemic stroke. If they do not have an
ATE, they face a range of neurological outcomes, now
modified by the efficacy of rFVIIa.
Assumptions
Time Horizon of Analysis – We used a time frame for the
analysis of one year. Data from the Phase II trial was used
for 90 day outcomes, including incremental direct costs of
care for use of rFVIIa and complications of ATE. We then
modeled an additional 9 months to capture mid-term
outcomes and costs, including direct costs accrued for
nursing home (NH) stay if necessary, and for inpatient or
outpatient rehabilitation in the post-ICH setting as appro-
priate to the mRS outcome. Since we hypothesized that
rFVIIa would result in improved clinical outcomes and a
mCER that would be acceptable from a societal perspec-
tive, any bias introduced into the analysis by not incorpo-
rating a longer analytic time horizon would be against the
active intervention with rFVIIa. Therefore, if rVIIa is "cost-
effective" in the shorter term, an analysis over the longer
term would only accentuate the differences, by increasing
the marginal effectiveness in long-term survivors with
improved neurological outcomes, and possibly by
decreasing the marginal cost.
Cost
To simplify the analysis, only incremental direct costs dur-
ing the index hospitalization were considered. We
assumed that among patients eligible for rFVIIa, there
would be no substantial cost differences in care between
the two strategies (rFVIIa vs. usual care) except: 1) cost of
rFVIIa; 2) cost of adverse events from rFVIIa; and 3) differ-
ential costs of outcomes, including disposition to home
vs. NH and outpatient vs. inpatient rehabilitation. Given
Figure 1BMC Neurology 2008, 8:17 http://www.biomedcentral.com/1471-2377/8/17
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the short time frame of the model we did not discount
costs.
The adverse event of greatest significance noted in the
Phase II trial was the increased risk of arterial thromboem-
bolism. We made the assumption that 50% of these ATE
events were ischemic strokes (IS) and 50% were myocar-
dial infarctions (MI) based on data from a recent review of
complications with rFVIIa use [12]. Thus, to model the
cost of the ATE complications, we used an average cost of
inpatient stay for IS and MI (0. 5 × IS inpatient stay cost +
0. 5 × cost of MI inpatient stay) as provided in the 2006
American Heart Association Statistical Update [13].
We made several simplifying assumptions about the costs
of the various neurologic outcomes. For mRS 0–1 ("mild
impairment"), we assigned outpatient rehabilitation costs
only. Patients with a mRS of 2 can usually go home with
assistance after ICH, while those with a mRS of 3 usually
require NH residence. Thus half of the mRS 2–3 patients
("moderate impairment") were assigned NH costs and
half were discharged to home with outpatient rehabilita-
tion costs (no incremental NH costs). For mRS 4–5
("severe impairment"), we assigned permanent NH resi-
dence for one year.
Review of the Data
Clinical Outcomes and Utilities
We used previously published utilities for stroke out-
comes derived from time-trade off analyses. These studies
have shown that time-trade off data are least prone to
biases [14]. In our model, a mRS of 4–5 mapped to an
ICH with "severe" neurological sequelae, while mRS of 2–
3 and 0–1 mapped to "moderate" and "mild" sequelae,
respectively.
Utilities for mRS 0–1 were derived from Gage et al [15].
Utilities for mRS 2–3 and 4–5 are derived from Post's sys-
tematic review of the literature [14]. For each outcome
state, a base case estimate and a utility range are presented,
including a negative utility for mRS of 4–5 since some
patients consider this outcome to be worse than death
(see Table 1). Ranges are modeled upon those used by
Fagan et al [3]. Survivors of ATE were arbitrarily assigned
a 55% decrease in the expected utility for the post-ICH
mRS (from the 80 ug/kg group) due to the further insult
of the ATE. This adjustment in utility is based upon the
assumption that the major impact of ATE's would be
ischemic strokes with "moderate" long-term neurologic
impairment.
Probabilities and Rates
The rate of ATE among all patients treated with rFVIIa in
the Phase II trial was 2% [9]. The assigned probability of
dying after an ATE was 29%, based on data from a recent
review of complications with rFVIIa use [12].
Costs
Information about the cost of rFVIIa was obtained from
the University of Cincinnati pharmacy. For an 80 mcg/kg
dose in an 80 kg patient, the cost of rFVIIa is $6,408 (per-
sonal communication, K. Sangha, PharmD, 2/16/2006).
Costs of rehabilitation and NH residence were derived
from Fagan et al and Holloway et al;[3,16] 1998 costs
were adjusted to 2005 US dollars via The Inflation Con-
verter [17]. Costs (and ranges for sensitivity analyses) are
presented in Table 2.
Results
In the "base case" analysis, the strategy of treating ICH
with rFVIIa dominates the usual care strategy by being
both more effective and less costly (see Table 3).
We performed a variety of one-way sensitivity analyses to
determine how robust our results were in the face of some
uncertain input parameter values. We also wanted to
explore potential future changes in the cost of therapy and
the evolving efficacy data for rFVIIa. First, we varied the
direct cost of neurological outcomes to the highest and
lowest costs in the proposed range, respectively. Not sur-
prisingly, when costs of poor neurologic outcome are
higher than the base case, treatment with rFVIIa domi-
nates conventional therapy. At the lowest costs for out-
comes in our range, costs become virtually identical;
rFVIIa is more expensive (by only $14) but has signifi-
Table 1: Model parameters
Probabilities
Variable No RX rFVIIa (40 mcg) rFVIIa (80 mcg) Utilities Range
Mild post-ICH deficit (mRS 0–1) 0. 08 0. 17 0. 21 0. 81 0. 70–0. 95
Moderate post-ICH deficit (mRS 2–3) 0. 23 0. 29 0. 29 0. 55 0. 2–0. 65
Severe post-ICH deficit (mRS 4–5) 0. 40 0. 37 0. 30 0. 25 (-0. 2)-0. 45
Death after ICH 0. 29 0. 18 0. 18 0 0
Arterial thromboembolic event 0. 02 0. 02 0. 55
Probability of dying after ATE 0. 29 0. 29BMC Neurology 2008, 8:17 http://www.biomedcentral.com/1471-2377/8/17
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cantly greater effectiveness, favoring the rFVIIa strategy
with a mCER of $129 per QALY.
We also performed sensitivity analyses on the cost of
rFVIIa. The base case cost per dose of rFVIIa is $6,408.
rFVIIa remains the dominant strategy unless the cost per
dose exceeds $7,500. At higher costs per dose, the mCER
remains less than $50,000/QALY until the cost per dose
surpasses $14,500. These results are presented in Figure 2,
along with sensitivity analyses in which the lowest and
highest costs of neurologic outcomes were varied from the
base case costs. Even if we assume the lowest cost of neu-
rologic outcomes in the model, the rFVIIa strategy is 'cost
effective' (less than $50,000/QALY) until the cost per dose
exceeds $13,000, and dominates unless the cost per dose
exceeds $6,250, which is just slightly lower than the base
case cost of $6,408.
In sensitivity analyses examining the probability of arte-
rial thromboembolic complications (ATE), rFVIIa domi-
nates conventional treatment unless the probability of
ATE exceeds 15% (base case – 2%) and the mCER remains
less than $50,000/QALY unless the probability of ATE
exceeds 29%. Conventional therapy becomes less costly
and more effective only if the probability of ATE exceeds
36%. Results are presented in Figure 3.
Since efficacy is frequently overestimated in early clinical
trials, we also explored the impact of changes in the effi-
cacy of rFVIIa to ensure that our results would not under-
estimate the mCER of rFVIIa. We first considered the
possibility that the true efficacy might be only as good as
the results for the 40 ug/kg dose from the Phase II trial
(see Table 1). Even when substituting these less effective
neurological outcomes into the base case model, treat-
ment with rFVIIa costs little for the benefit it produces
with a mCER of $9,541 per QALY.
Further multi-way sensitivity analyses were performed
assuming the lower efficacy of the 40 mcg/kg dose. When
using these outcomes and varying the probability of
developing ATE, the ATE rate must still exceed 18% for the
cost-effectiveness ratio to exceed $50,000/QALY. In
another analysis using the lower efficacy of the 40 ug/kg
dose and varying the cost of rFVIIa, the rFVIIa strategy
dominates until the drug cost exceeds $5,250 and the
mCER does not exceed $50,000/QALY until the drug cost
is greater than $10,750.
We next explored the impact of changes in the efficacy of
rFVIIa in preventing major neurological sequelae (i. e.,
mRS 4–5) and in the efficacy of rFVIIa in preventing
death. As shown in Figure 4, as the efficacy in preventing
major neurological impairment increases, the marginal
cost-effectiveness of rFVIIa becomes smaller. Beyond an
efficacy of 18%, rFVIIa is both less expensive and more
effective than usual care. In Figure 5, we explore both the
efficacy of preventing major neurological sequelae (on the
horizontal axis) and the efficacy in preventing death (on
the vertical axis). A series of lines is shown for 3 different
thresholds for willingness-to-pay, $25K/QALY, $50K/
QALY, and $75K/QALY. These thresholds separate the
analytic space into two regions, one in which rVIIa is best
(the upper right) and one in which usual care is best (the
lower left). The base case values for these two efficacy
terms from the phase II study fall to the upper right, in the
region in which rFVIIa is favored. If one believes the
results of the phase III trial are correct (efficacy in prevent-
ing major neurological sequelae and in preventing death
equal zero), then usual care is best. For any combination
of efficacies greater than those falling along the $50K/
QALY willingness-to-pay threshold, rFVIIa has a reasona-
ble cost for the benefit gained. Should future studies dem-
onstrate these efficacies to be greater than those falling
along this threshold line, rFVIIa would be "cost-effective."
The results were insensitive to changes in a number of
other parameters including the probability of dying after
an ATE and the utility for neurological outcomes in survi-
Table 2: Economic assumptions
Outcomes Costs* Range
NH residence (one year) $46,346 $23,175 – $57,939
Inpatient rehabilitation $24,720 $11,588 – $46,351
Outpatient rehabilitation $2,591 $1,391 – $2,897
Severe stroke(mRS 4–5) $46,346 $23,175 – $57,939
Moderate stroke (mRS 2–3) $35,533 $15,000 – $45,000
Mild stroke (mRS 0–1) $2,591 $1,391 – $2,897
rFVIIa $6,408
Arterial thromboembolic event (ATE) $9,261
* 2005 US dollars.
Table 3: Base case analysis
Strategy Cost ($) Effectiveness (QALYs) Marginal Cost ($) Marginal Effectiveness (QALYs) Marg C/E ratio (Δ$/ΔQALYs)
rFVIIa $39,305 0. 40
Usual Care $40,359 0. 29 $1,053. 20 -0. 11 ********
******** no mCER because rFVIIa dominates usual care by being both more effective and less costly.BMC Neurology 2008, 8:17 http://www.biomedcentral.com/1471-2377/8/17
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vors of ischemic stroke or myocardial infarction (due to
ATE).
Discussion
Based upon the published results of the phase II trial, the
treatment of eligible ICH patients with rFVIIa would be
promising from both a clinical and economic point of
view, resulting in better outcomes at a lower cost than
conventional management. Our model is simple, and
only examines short-term cost-effectiveness, but accounts
for most of the relevant marginal costs and our conclu-
sions did not change over a variety of sensitivity analysis.
The bias introduced into our analysis by a short time hori-
zon should only make rFVIIa appear more costly and less
effective. Extending the time horizon of the analysis
would only increase the marginal effectiveness and per-
haps decrease the marginal cost of rFVIIa.
A more sophisticated modeling approach involving a
Markov state transition model has recently been pub-
lished [18]. The findings of this manuscript were similar
to ours in that rFVIIa was highly cost-effective. This analy-
sis examined the full range of doses tested in the Phase II
study, and while all doses were cost-effective the 80 ug
dose was both more effective and less costly. Their model
was robust, with stability across a wide range of 1-way sen-
sitivity analyses. Their results have the advantage of
Markov modeling across a longer time span, and took into
account long-term disability, expected mortality, and cost
multipliers (with appropriate discounting over time).
Their findings demonstrate that the high cost of poor out-
comes have much greater impact than medication costs,
and that extending the model to longer time frames only
enhances the incremental costs associated with poor out-
come (in the sensitivity analyses, the annual cost multi-
plier had the greatest impact on the incremental cost-
effectiveness ratio). This confirms that short term analyses
such as ours only bias against rFVIIa, and make our find-
ings of cost-effectiveness in the short term more robust.
In this recent publication, arterial thromboembolic events
that could result from treatment with rFVIIa were not con-
sidered. It is important to consider such adverse events, as
they impact upon costs, mortality, and long-term out-
come for survivors. Furthermore, patients with vaso-
occlusive disease were excluded from the Phase II trial,
and in an analysis of eligibility across a population, vaso-
occlusive disease was one of the most common exclusions
(for 36% of ICH patients) and thus significantly impacts
upon applicability of this therapy. It should be noted that
the Phase III trial did not exclude patients with a history
of vaso-occlusive disease, presumably to increase general-
Figure 2BMC Neurology 2008, 8:17 http://www.biomedcentral.com/1471-2377/8/17
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izability. Our data suggest that doing so is reasonable up
to a point, as treatment with rFVIIa remains 'cost-effective'
at higher levels of ATE.
Earnshaw et al [18]. found that drug costs only accounted
for between 1. 5–6% of the total lifetime medical costs in
their model. We found that the cost of rFVIIa would need
Figure 3
Figure 4BMC Neurology 2008, 8:17 http://www.biomedcentral.com/1471-2377/8/17
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to be increased substantially before the treatment strategy
exceeds the traditional threshold societal willingness to
pay of $50,000/QALY.
Our model is limited by the short time horizon consid-
ered, and the consideration of direct incremental costs
only. Earnshaw et al [18] included indirect medical costs
such as caregiver burden in their model. Inclusion of such
costs would only be expected to decrease the marginal
cost-effectiveness of treatment with rFVIIa.
At this time, there is no alternative medical treatment for
ICH. The benefits seen in the Phase II trial were promis-
ing, and even though only a minority of ICH patients
would be eligible for treatment with rFVIIa with the Phase
II trial inclusion and exclusion criteria, our results indicate
that such treatment is highly cost-effective and within
society's willingness to pay.
Results of the Phase III study (rFVIIa in Acute Hemor-
rhagic Stroke Treatment; FAST trial) have recently been
presented (Mayer et al, AAN meeting). These as yet
unpublished results showed that the rFVIIa intervention
did not result in superior clinical outcomes at 3 months,
which was the primary clinical endpoint of the trial. If
these results are reproducible and generalizable, the use of
rFVIIa would not be cost-effective as its use would result
in added cost with no increase in effectiveness. Perhaps,
the real answer lies somewhere in between the results of
these two studies. The sensitivity analysis shown in Figure
5 allows us to consider the impact of future trial results
that fall somewhere along this spectrum.
The discrepancy seen between the early clinical trials and
the FAST trial was discussed in the FAST results presenta-
tion. The data presented suggest a similar biologic effect as
noted in the Phase II trial, in that rFVIIa significantly lim-
ited hematoma expansion. However, based on a pre-
planned interim analysis, the sample size was increased
due to fewer poor outcomes than anticipated. In present-
ing the FAST trial results, the investigators noted that the
placebo group in the FAST trial had much better 3-month
outcomes than the placebo group in the Phase II trial,
leading to discrepant results despite a similar biologic
effect. In post-hoc analyses exploring the results, between-
group heterogeneity was seen for several key factors
related to mortality and outcome, especially for the oldest
patients in the trial, despite adequate randomization. For
example, the rFVIIa treated arms (20 ug and 80 ug) had a
higher proportion of patients with cardiac disease (left
ventricular hypertrophy pattern on EKG) and a higher
proportion of patients with intraventricular extension of
the hematoma. Notably, all three arms had similar rates of
venous thromboembolic events, and the high dose rFVIIa
arm had a 10% rate of ATE vs. 5% in the placebo arm.
A post-hoc analysis performed by the investigators, sug-
gested that the benefit of rFVIIa might have been realized
in the Phase III trial had there been minor changes in
inclusion and exclusion criteria, Specifically, the post-hoc
analysis suggested that benefit would be greatest if one
Figure 5BMC Neurology 2008, 8:17 http://www.biomedcentral.com/1471-2377/8/17
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excluded patients with later treatment (> 180 minutes)
and age > 75.
Conclusion
In light of our results, and those of Earnshaw and col-
leagues, we believe that another Phase III trial should be
considered. Our analysis shows that the ATE rates seen in
the FAST trial are well within the limits of potential cost-
effectiveness, and given that the biologic effect was similar
in the Phase II trial and the FAST trial similar cost-effec-
tiveness might be found with appropriate revision of the
inclusion/exclusion criteria. We await the publication of
the FAST results so that our model can be applied in the
hopes of providing estimates of this potential cost-effec-
tiveness. Until further studies of this type are performed,
ICH remains a disease with high morbidity and mortality,
with no effective medical treatment.
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